We won’t know whether Omicron evades COVID vaccines for another few weeks. Here’s why.
- Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
Preliminary evidence suggests Lambda has an easier time infecting our cells and is a bit better at dodging our immune systems. But vaccines should still do a good job against it.
A vaccine expert breaks down everything you need to know about Australia’s newest COVID-19 vaccine candidate.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
We’ve gone from a novel virus to several COVID-19 vaccines in less than a year. Here’s what we’ve learned from earlier vaccines to allow this to happen.
If the vaccine had been widely rolled out, people would think they had HIV when they didn’t. But it’s not the end of this type of technology.
At least three Chinese vaccines have been approved for emergency use, while phase 3 clinical trials are ongoing.
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
Australia’s contribution to the global COVAX initiative helps secure future vaccines. Here’s the full field of candidates.
From adenoviruses to RNA: the pros and cons of different COVID vaccine technologies
Contact Adam for
- General
- Media request
- Speaking request
- Consulting / Advising
- Research collaboration
- Research supervision
- Location: Gold Coast, Australia
- Website
- X (formerly Twitter): @adamtaylor200
- Article Feed
- ORCID
- Joined
